Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry.
Adrenal Cortex Hormones
/ therapeutic use
Adult
Antibodies, Monoclonal, Humanized
/ adverse effects
Blepharitis
/ chemically induced
Conjunctivitis
/ chemically induced
Dermatitis, Atopic
/ drug therapy
Drug Resistance
Drug Therapy, Combination
Female
Follow-Up Studies
Humans
Immunosuppressive Agents
/ therapeutic use
Male
Middle Aged
Netherlands
/ epidemiology
Prospective Studies
Receptors, Interleukin-4
/ antagonists & inhibitors
Registries
Young Adult
atopic dermatitis
daily practice
disease severity
dupilumab
effectiveness
long-term
safety
Journal
Journal of the American Academy of Dermatology
ISSN: 1097-6787
Titre abrégé: J Am Acad Dermatol
Pays: United States
ID NLM: 7907132
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
04
04
2020
revised:
27
08
2020
accepted:
30
08
2020
pubmed:
19
9
2020
medline:
26
8
2021
entrez:
18
9
2020
Statut:
ppublish
Résumé
Real-life data on long-term effectiveness and safety of dupilumab in atopic dermatitis patients are limited. To study 52-week effectiveness and safety of dupilumab in a prospective multicenter cohort of adult patients with treatment-refractory atopic dermatitis. Patients treated with dupilumab and participating in the Dutch BioDay registry were included. Clinical effectiveness and safety were evaluated. Two hundred ten atopic dermatitis patients were included. Mean percentage change in Eczema Area and Severity Index score after 16 weeks was -70.0% (standard deviation 33.2%) and further decreased to -76.6% (standard deviation 30.6%) by week 52. A greater than or equal to 75% improvement in the score was achieved by 59.9% of individuals by week 16 and by 70.3% by week 52. The most reported adverse effect was conjunctivitis (34%). Limited patients (17; 8.1%) discontinued dupilumab treatment. Because of the lack of a control group and observational design, factors of bias may have been induced. Treatment with dupilumab resulted in a rapid improvement in clinical outcome measures, and effectiveness further improved during the 52-week follow-up period.
Sections du résumé
BACKGROUND
BACKGROUND
Real-life data on long-term effectiveness and safety of dupilumab in atopic dermatitis patients are limited.
OBJECTIVE
OBJECTIVE
To study 52-week effectiveness and safety of dupilumab in a prospective multicenter cohort of adult patients with treatment-refractory atopic dermatitis.
METHODS
METHODS
Patients treated with dupilumab and participating in the Dutch BioDay registry were included. Clinical effectiveness and safety were evaluated.
RESULTS
RESULTS
Two hundred ten atopic dermatitis patients were included. Mean percentage change in Eczema Area and Severity Index score after 16 weeks was -70.0% (standard deviation 33.2%) and further decreased to -76.6% (standard deviation 30.6%) by week 52. A greater than or equal to 75% improvement in the score was achieved by 59.9% of individuals by week 16 and by 70.3% by week 52. The most reported adverse effect was conjunctivitis (34%). Limited patients (17; 8.1%) discontinued dupilumab treatment.
LIMITATIONS
CONCLUSIONS
Because of the lack of a control group and observational design, factors of bias may have been induced.
CONCLUSION
CONCLUSIONS
Treatment with dupilumab resulted in a rapid improvement in clinical outcome measures, and effectiveness further improved during the 52-week follow-up period.
Identifiants
pubmed: 32946967
pii: S0190-9622(20)32618-9
doi: 10.1016/j.jaad.2020.08.127
pii:
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Antibodies, Monoclonal, Humanized
0
Immunosuppressive Agents
0
Receptors, Interleukin-4
0
dupilumab
420K487FSG
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1000-1009Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2020. Published by Elsevier Inc.